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Abstract
Background: Granulovacuolar degeneration (GVD) is one of the pathological hallmarks of Alzheimer’s disease (AD), and it is
defined as electron-dense granules within double membrane-bound cytoplasmic vacuoles. Several lines of evidence have
suggestedthatGVDsappearwithinhippocampalpyramidalneuronsinADwhenphosphorylatedtaubeginstoaggregateinto
early-stage neurofibrillary tangles. The aim of this study is to investigate the association of GVDs with phosphorylated tau
pathologytodeterminewhetherGVDs and phosphorylated taucoexist among different non-ADneurodegenerativedisorders.
Methods: An autopsied series of 28 patients with a variety of neurodegenerative disorders and 9 control patients were
evaluated. Standard histological stains along with immunohistochemistry using protein markers for GVD and confocal
microscopy were utilized.
Results: The number of neurons with GVDs significantly increased with the level of phosphorylated tau accumulation in the
hippocampal regions in non-AD neurodegenerative disorders. At the cellular level, diffuse staining for phosphorylated tau
was detected in neurons with GVDs.
Conclusions: Our data suggest that GVDs appear in relation to hippocampal phosphorylated tau accumulation in various
neurodegenerative disorders, while the presence of phosphorylated tau in GVD-harbouring neurons in non-AD
neurodegenerative disorders was indistinguishable from age-related accumulation of phosphorylated tau. Although GVDs
in non-AD neurodegenerative disorders have not been studied thoroughly, our results suggest that they are not incidental
findings, but rather they appear in relation to phosphorylated tau accumulation, further highlighting the role of GVD in the
process of phosphorylated tau accumulation.
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Introduction
Granulovacuolar degeneration (GVD) is one of the pathological
hallmarks of Alzheimer’s disease (AD) [1] and is defined as
electron-dense granules within double membrane-bound cytoplas-
mic vacuoles, mainly in the hippocampal pyramidal neurons [2].
Attempts to define the molecular composition of GVDs by
immunohistochemical methods led to the identification of a large
number of possible protein constituents, suggesting a link between
GVD and AD-related neurodegeneration. For example, the tau
protein found in GVD complexes is antigenically related to that
found in paired helical filaments in AD, although antibodies to
other forms of tau do not recognize GVDs [3,4,5,6]. Activation of
caspase 3, an apoptotic effector protease involved in cleavage of
tau [7] and amyloid precursor protein [8], has been found in
GVDs, but rarely in other pathological structures [9,10,11,12].
The protein kinases glycogen-synthase kinase 3 and casein kinase
1, which phosphorylate tau, are also markers of GVD
[13,14,15,16,17]. Phosphorylated pancreatic endoplasmic reticu-
lum kinase, a marker of a cellular stress response to unfolded
protein, which is increased in AD, is associated with GVD [18].
Intraneuronal dot-like structures morphologically similar to GVDs
were also labelled by phosphorylation-dependent TAR DNA
binding protein (TDP43) antibody [19], in line with the abnormal
TDP43 immunoreactivity reported in AD [20,21,22,23,24,25].
Furthermore, both proteasome and endosome pathway dysfunc-
tion may be present in GVD-containing cells, as GVD has been
detected by antibodies to a cellular marker of proteasome
degradation, ubiquitin (Ub) [2,26], to intermediaries in the
ubiquitin system, phospho-b-catenin [27] and Pin1 [28], and to
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2b (CHMP2B) [29,30]. In relation to other pathognomonic
features, several lines of evidence have suggested that GVDs
appear within the hippocampal pyramidal neurons in AD when
phosphorylated tau begins to aggregate into early-stage neurofi-
brillary tangles (NFTs) [11,15,18,31].
However, GVDs are not AD-specific hallmark: they have been
reported within the hippocampal pyramidal neurons in normal
aged brain [32], as well as in other diseases such as progressive
supranuclear palsy (PSP) [33], pantothenate kinase-associated
neurodegeneration (PKAN) [34], corticobasal degeneration (CBD)
[35] and Pick’s disease (PiD) [36]. Given that all these disorders
can present with pathological lesions containing phosphorylated
tau protein, these findings raise the possibility that GVDs may also
appear in relation to the hippocampal phosphorylated tau
accumulation in non-AD neurodegenerative disorders.
Recently, we have shown that an antibody to CHMP2B can
specifically detect GVDs within hippocampal pyramidal neurons in
AD [29]. The high sensitivity and specificity of this antibody were
later confirmed by another group [30]. CHMP2B is a component of
the endosomal sorting complex required for transport III (ESCRT-
III), which is involved in endocytic trafficking of proteins [37].
ESCRT-III drives the formation and specifically the scission of
intraluminal vesicles in multivesicular bodies, and under certain
conditions remains associated with them.
To better understand GVD formation, particularly focusing on
its relationship with the accumulation of phosphorylated tau, we
examined GVDs in non-AD neurodegenerative disorders. The
aims of the present study were: (1) to compare the CHMP2B
immunopositivity of the hippocampal GVDs in several neurode-
generative disorders that can present with pathological lesions
containing phosphorylated tau protein; and (2) to investigate the
association of CHMP2B-positive GVDs with tau pathology, to
determine whether CHMP2B-positive GVDs and phosphorylated
tau coexist among non-AD neurodegenerative disorders.
Results
CHMP2B-positive granules correspond to GVDs in the
hippocampal neurons from patients with several
neurodegenerative disorders
Immunohistochemical localization of CHMP2B was investigat-
ed in the hippocampus of several neurodegenerative disorders,
including MyD, ALS-D, PDD, MSA, PiD, PSP and PKAN cases.
As reported, CHMP2B immunoreactivity was observed as
granules in pyramidal neurons. No immunoreactivity was detected
in glial cells. CHMP2B-positive granules were often surrounded by
a clear halo and were morphologically similar to the classic
granules of GVD.
To confirm the GVD nature of these CHMP2B-positive
granules, sections were stained once with hematoxylin and eosin
(Fig. 1A, B, E, F, I, J). After observing GVDs in the hippocampus,
these stained sections were de-stained in absolute ethanol, and
processed for CHMP2B immunohistochemical analysis (Fig. 1C,
D, G, H, K, L). Most neurons with GVDs showed CHMP2B-
positive granules and these CHMP2B-positive granules corre-
sponded to GVDs. Together with our previous results, this
suggested that CHMP2B could be used as a molecular label to
study GVD in non-AD neurodegenerative disorders. The numbers
of neurons with CHMP2B-positive GVDs/mm
2 in each case are
listed in Table S1.
CHMP2B-positive GVDs colocalize with pSmad2/3 and
ubiquitin
Since GVDs have been reported to be immunoreactive for
pSmad2/3 [38] and Ub [2,26], we assessed the colocalization of
CHMP2B-positive GVDs and these markers using double
immunofluorescent labeling. In the hippocampus of several
neurodegenerative disorders, including MyD, ALS-D, PDD,
MSA, and PKAN cases, almost all CHMP2B-positive GVDs
were also immunopositive for pSmad2/3 and Ub (Fig. 2). The
colocalization of CHMP2B-positive GVDs and these markers
could also be observed even in PSP (Fig. 2J, K, L, JJ, KK, LL) and
MSA-C cases (Fig. 2G, H, I, GG, HH, II), in which hematoxylin
and eosin staining revealed relatively few GVDs that we could not
confirm the GVD nature of CHMP2B-positive granules.
To investigate the reliability of using CHMP2B as a molecular
label to study GVDs, we next examined the correlation between
the number of neurons with CHMP2B-positive GVDs and the
number of neurons with granules immunopositive for pSmad2/3
or Ub. As shown in Figure 3A, immunohistochemistry with the
anti-CHMP2B antibody detected GVDs in a similar number of
cells to those immunoreactive for pSmad2/3 or Ub within the
hippocampal region in each of the diseases studied.
CHMP2B-positive GVDs correlate with hippocampal tau
pathology phosphorylated at Ser-202 and Thr-205
Our research interest was the association of CHMP2B-positive
GVDs with tau pathology in the hippocampus, including the
subiculum, CA2 and CA1 subfields, where GVDs were found in
high number in AD as well as non-AD cases [18,39]. Therefore we
directly compared the number of hippocampal neurons with
CHMP2B-positive GVDs with the number of neurons positive for
phosphorylated tau. The number of neurons positive for
phosphorylated tau was assessed using our method for scoring
tangle densities (for details see the Material and Methods). We also
investigated the association between neurons with CHMP2B-
positive GVDs and classic Braak NFT stage. The phosphorylated
tau score (p-tau score) and Braak stage score in each case are listed
in Table 1, right column.
When age at death was controlled, strong correlations were
observed between both the number of neurons with CHMP2B-
positive GVDs and p-tau score (r=0.63, p,0.01) as well as
CHMP2B-positve GVDs and Braak NFT stage (r=0.77, p,0.01)
across the entire sample. Strong correlations were also observed
when we excluded AD cases from the analysis (r=0.60, p,0.01,
Fig. 3B, r=0.73, p,0.01, Fig. 3C, respectively).
We next investigated the correlation between CHMP2B-
positive GVDs and phosphorylated tau at the cellular level. For
immunohistochemistry, we used the AT8 antibody, which
recognizes tau phosphorylated at Ser-202 and Thr-205. In
addition to NFTs, in AD and other neurodegenerative diseases
AT8 stains some non-tangle-bearing pyramidal neurons, indicative
of hyperphosphorylated tau in a pre-tangle stage [40]. While no or
very few CHMP2B-positive GVDs were observed in neurons with
NFTs immunoreactive for AT8, diffuse staining for phosphory-
lated tau was observed in neurons with CHMP2B-positive GVDs
in several neurodegenerative disorders, except for the cases in
which immunohistochemistry revealed relatively few CHMP2B-
immunoreactive neurons (Table S1 and Fig. 4). Together, these
data indicate that CHMP2B-positive GVDs appear in association
with the accumulation of phosphorylated tau in several neurode-
generative disorders.
GVDs in Various Neurodegenerative Disorders
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In this study, we demonstrated that CHMP2B-positive granules
corresponded to GVDs in a variety of neurodegenerative
disorders. The GVD nature of these CHMP2B-positive granules
was demonstrated on morphological grounds and because of the
strong co-localization upon both HE staining and with other GVD
markers including pSmad2/3 [38] and Ub [2,26]. In addition, the
number of CHMP2B-positive GVDs was comparable with that of
neurons with granules immunopositive for the GVD markers
(pSmad2/3 and Ub) among the different diseases. Indeed, while
GVDs are often assumed to be a pathological entity associated
with AD, they have been described within the hippocampus in a
number of neurodegenerative diseases; in a preceding investiga-
tion, other GVD markers including CK1 delta [17] and p-SAPK/
JNK [41] also confirmed the presence of GVDs in the brains of
patients with non-AD neurodegenerative disorders. Compared
with p-SAPK/JNK, with which immunohistochemistry revealed
pathological accumulations of NFTs in addition to GVDs [41], the
advantage of CHMP2B as well as CK1 delta as a GVD marker is
that it specifically stains GVDs but no other coexisting structures.
Taken together, it is reasonable to argue that along with CK1
delta, CHMP2B is a robust marker of GVD in that it specifically
detected GVD in AD as well as in non-AD neurodegenerative
disorders.
In AD, several lines of evidence have suggested that GVDs
appear within the hippocampal pyramidal neurons when phos-
phorylated tau begins to aggregate into early-stage NFTs
[11,15,18,31]; however, whether one can adapt this relationship
to non-AD diseases had not yet been systematically examined [42].
In this study, we showed that the number of neurons with
CHMP2B-positive GVDs increased in association with phosphor-
ylated tau accumulation in the hippocampus not only in AD but
also in a wide range of non-AD neurodegenerative disorders. In
addition, we provided direct evidence that diffuse staining for
phosphorylated tau could be detected in neurons with CHMP2B-
positive GVDs in most of the non-AD cases including PSP and
PDD. The pathological forms of tau from AD and PDD patients
demonstrate four bands on western blots (72, 68, 64, and 60 kDa;
Type I pattern) [43,44], while pathological tau from PSP [45]
demonstrates three bands (72, 68, and 64 kDa; Type III pattern).
Unfortunately, we could not show colocalization of CHMP2B-
positive GVDs with phosphorylated tau in PiD, which demon-
strates two bands (64 and 60 kDa; Type II pattern) on western
blots [46,47], probably because of the small number of neurons
with CHMP2B-positive GVDs. Therefore, our results suggested
that in most hippocampal neurons harboring GVDs, they appear
in relation to phosphorylated tau accumulation in non-AD
neurodegenerative disorders including the ‘tauopathies’. However,
further studies are needed to clarify whether GVDs appear in
relation to phosphorylated tau in tauopathies, irrespective of the
phosphorylated tau isoforms.
The most notable finding of the present study is the presence of
GVDs in the phosphorylated tau-containing neurons in various
neurodegenerative disorders other than AD. Although this finding
raises the possibility that there is a common mechanism for GVD
formation and phosphorylated tau accumulation, the cellular fates
of GVD-harboring neurons may differ between AD and non-AD
disorders. Previous studies have suggested that neurons harboring
GVDs with phosphorylated tau accumulation reflected ‘toxic’ or
‘apoptotic’ alterations in AD [11,18], based on their relationship
with phosphorylated tau, whose degree of accumulation correlates
with neuronal loss in the hippocampus [42,48,49], as well as the
hippocampal vulnerability, both of which have been extensively
characterized and documented in AD [50]. Moreover, an
exponential relationship exists between the number of GVDs
Figure 1. CHMP2B-positive granules correspond to GVDs. Cellular localization of CHMP2B (C, D, G, H, K, L) compared with hematoxylin and
eosin (HE) staining (A, B, E, F, I, J) in several neurodegenerative disorders is shown. CHMP2B-positive structures colocalized with the GVDs identified
by HE staining and surrounded by a clear halo. A, C, Alzheimer’s disease; B, D, myotonic dystrophy; E, G, amyotrophic lateral sclerosis with dementia;
F, H, Pick’s disease; I, K, multiple system atrophy with parkinsonism; J, L, pantothenate kinase-associated neurodegeneration. Scale bars represent
20 mm.
doi:10.1371/journal.pone.0026996.g001
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between tau accumulation and cognitive decline or neuronal loss
does not necessarily exist in other disorders [51,52], and it is not
known whether the same exponential relationship applies to non-
AD cases [42]. Therefore, it is unclear whether hippocampal
neurons harboring GVDs with tau accumulation observed in non-
AD disorders are pathognomonic for phosphorylated tau-related
neurodegeneration, or perhaps are an underlying toxic moiety.
It is unclear whether the presence of phosphorylated tau in the
hippocampus of non-AD cases is necessarily more than a result of
normal aging. Tau proteins can become insoluble with aging and
sometimes contaminate the preparations of the so-called patho-
logical tau aggregates [53]–indeed this contamination has been
described in several neurodegenerative diseases [54,55,56].
Moreover, the NFT burden to discriminate between the aging
and AD has been thought to be quantitative rather than
qualitative [57,58]. Therefore, given that our study lacks age-
matched controls, we are uncertain whether the presence of
phosphorylated tau in the hippocampus of non-AD cases reflects
aging, a substantial AD process, or a disease-specific finding.
Nonetheless, strong correlations were observed in our cases
between the number of neurons with CHMP2B-positive GVDs
and phosphorylated tau burden, even when we excluded AD cases
from the analysis. This suggests that, whatever the mechanism
involved in phosphorylated tau accumulation, GVDs appear in
relation to hippocampal phosphorylated tau accumulation in
various neurodegenerative disorders.
Conclusions
In summary, using an antibody to CHMP2B as a molecular
label for GVDs [29], we have shown that GVDs appear
consistently with hippocampal phosphorylated tau accumulation
Figure 2. CHMP2B-positive GVDs colocalize with pSmad2/3 and ubiquitin. Hippocampal sections were stained with both anti-CHMP2B
antibody (A, D, G, J, M, AA, DD, GG, JJ, MM, green) and antibodies against pSmad2/3(B, E, H, K, N, red) or ubiquitin (BB, EE, HH, KK, NN, red).
CHMP2B-positive GVDs colocalized with pSmad2/3 and ubiquitin, although their colocalization rates varied. C, F, I, L, O, CC, FF, II, LL, OO, merged
images counterstained with Hoechst Dye (blue). A, B, C, AA, BB, CC, amyotrophic lateral sclerosis; D, E, F, DD, EE, FF, pantothenate kinase-
associated neurodegeneration; G, H, I, GG, HH, II, multiple system atrophy with cerebellar ataxia; J, K, L, JJ, KK, LL, progressive supranuclear palsy;
M, N, O, MM, NN, OO, Parkinson disease with dementia. Scale bars represent 20 mm.
doi:10.1371/journal.pone.0026996.g002
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PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e26996Figure 3. Correlation between the numbers of CHMP2B-positive GVDs with numbers of GVDs immunoreactive for pSmad2/3 or Ub
and hippocampal tau pathology. A: Number of neurons with CHMP2B-positive GVDs plotted against those with GVDs immunoreactive for
pSmad2/3 (blue filled circles) or ubiquitin (Ub; red open circles). The Pearson correlation coefficient for pSmad2/3 and ubiquitin was 0.935 (p,0.01) and
0.888 (p,0.01), respectively, among all the cases studied. Each circle represents an individual hippocampus investigated. B: Relationship between
phosphorylated tau score (p-tau score) and the number of neurons with CHMP2B-positive GVDs in non-Alzheimer’s disease (AD) neurodegenerative
disorders. The number of neurons with CHMP2B-positive GVDs increased significantly with the score for phosphorylated tau pathology (r=0.60,
p,0.01). Each closed circle represents an individual non-AD hippocampus investigated. Each open circle represents an individual hippocampus from
an AD case, for reference. C: CHMP2B-positive GVD burden in the hippocampus with respect to Braak NFT stage in non-Alzheimer’s disease (AD)
GVDs in Various Neurodegenerative Disorders
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AD neurodegenerative disorders have not been studied thorough-
ly, our results suggested that they are not incidental findings but
rather they appear in relation to phosphorylated tau accumula-
tion, further highlighting the role of GVD in the process of
phosphorylated tau accumulation.
Materials and Methods
Ethics Statement
The protocols for neuropathological procedures and analysis
were approved by and performed under the guidelines of the
ethics committee of Hiroshima University Graduate School of
Biomedical Sciences. The neurodegenerative disorders and control
samples were obtained with the adequate understanding and
written informed consent of family members. For this study, all
samples were coded and personal information dissociated from the
test results. All the data were analyzed anonymously, and all
neuropathological procedures and analysis have been conducted
according to the principles expressed in the Declaration of
Helsinki.
Brain pathology and staining
Four cases of AD, five cases of myotonic dystrophy (MyD), eight
cases of amyotrophic lateral sclerosis, two cases of ALS with
dementia (ALS-D), three cases of Parkinson disease with dementia
(PDD), and one case each of multiple system atrophy with
parkinsonism, multiple system atrophy with cerebellar ataxia
(MSA-C), PiD, PSP, CBD, and PKAN, and nine control cases
without neurodegenerative disorders according to clinical history
and confirmed by thorough neuropathological examination were
selected (for case demographics see Table S1, postmortem delays
4–24 hours).
Formalin-fixed, paraffin-embedded tissues including the hippo-
campus and the parahippocampal gyrus were sliced at a thickness
of 7 mm. The sections were deparaffinized and then immuno-
stained with primary antibody. The primary antibodies used were
as follows: rabbit polyclonal antibody to CHMP2B (ab33174,
dilution 1:600; Abcam, Cambridge, UK); mouse monoclonal
antibody to ubiquitin (MAB1510, dilution 1:2,000; Chemicon,
Temecula, CA); goat polyclonal antibody to pSmad2/3 (sc-11769,
dilution 1:400; Santa Cruz Biotech, Santa Cruz, CA); and mouse
monoclonal antibody to phosphorylated tau (AT8, dilution 1:800;
Innogenetics, Gent, Belgium). For antigen retrieval, the slides were
microwaved in distilled water for 10 min then washed in
phosphate-buffered saline (PBS) for 5 min. Deparaffinized sections
were then incubated with 1% H2O2 in methanol for 20 min to
eliminate endogenous peroxidase activity. Each section was
incubated with primary antibody overnight at 4uC. After washing
in PBS, the sections were incubated with horseradish peroxidase
(HRP)-conjugated goat anti-mouse antibody or goat anti-rabbit
antibody (both diluted 1:100; DAKO, Glostrup, Denmark) for
30 min at room temperature. The sections were then washed three
times in PBS and incubated at room temperature with 3,39-
diaminobenzidine (DAKO). All sections were counterstained with
hematoxylin.
In addition, we performed double staining on sections including
those of the hippocampus and the parahippocampal gyrus of the
disease cases. We applied the same primary antibodies as
described above. These primary antibodies were detected with
the following secondary antibodies (dilution 1:500; Molecular
Probes, Eugene, OR): Alexa Fluor 488 donkey anti-rabbit IgG,
Alexa Fluor 546 donkey anti-mouse IgG, Alexa Fluor 546 donkey
anti-goat IgG, Alexa Fluor 488 goat anti-mouse IgG, and Alexa
Fluor 546 goat anti-mouse IgG. 0.5% Sudan black in 70% ethanol
was used to quench autofluorescence before mounting the
paraffin-embedded sections. The slides were mounted with
Vectashield (Vector Laboratories, Burlingame, CA), and observed
under a fluorescence microscope (BIOREVO BZ-9000; Keyence,
Osaka, Japan) or an LSM510 confocal laser scanning microscope
(Carl Zeiss AG, Oberkochen, Germany).
We assessed the staining specificity by replacing the primary
antibodies with an appropriate amount of non-immune rabbit
serum or PBS containing 3% bovine serum albumin or by pre-
incubating the primary antibodies with an excess of peptide
immunogen. No reaction products were seen in the sections thus
treated (data not shown).
Quantitative analysis
For all cases, we counted the number of neurons with
CHMP2B-positive GVDs and neurons with granules immunopo-
sitive for pSmad2/3 and Ub in the hippocampus at 4006
magnification. For the analysis of the correlation to the tau
pathology, the number of neurons with CHMP2B-positive GVDs
was expressed as neurons/mm
2; we used a mean number of three
independent measures using light microscopy at 4006magnifica-
tion and the images of total hippocampal area in each case were
measured by the Image J (NIH) software.
The accumulation of phosphorylated tau in the hippocampus
was evaluated using the grading score of Mo ¨lsa ¨ with some
modifications [59]. Briefly, AT8-stained sections including the
hippocampus were scanned using light microscopy at 1006
magnification. Five randomly selected fields, each measuring
0.92 mm
2, were selected, and the mean number of neurons
positive for phosphorylated tau in each field was calculated
(Table 1). A lesion score was then assigned, ranging from 0 to 10.
Table 1. Scoring system used to quantify neurons with
phosphorylated tau.
Structures per field
phosphorylated tau score
(p-tau score)
00
1–2 1
3–4 2
5–9 3
10–14 4
15–19 5
20–24 6
25–29 7
30–34 8
35–40 9
. 40 10
doi:10.1371/journal.pone.0026996.t001
neurodegenerative disorders. The number of neurons with CHMP2B-positive GVDs increased significantly with respect to Braak NFT stage (r=0.73,
p,0.01). Each closed circle represents an individual non-AD hippocampus investigated. Each open circle represents an individual hippocampus from
an AD case for reference.
doi:10.1371/journal.pone.0026996.g003
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density were 10–14 and the highest 26–30, the range would be 10–
30, giving a midpoint of 20 and phosphorylated tau score (p-tau
score) of 6. If the highest density were over 40, the arbitrary figure
of 45 was used when calculating the midpoint. Braak staging was
determined by AT8 immunostaining of neurofibrillary tangles in
hippocampus and isocortical brain regions [60].
Statistical evaluations were performed with the SPSS 14
software package (SPSS, Chicago, Illinois). Due to the exploratory
nature of our investigation, the level of significance was set to .05
(two-tailed tests). To avoid effects of aging, we used partial
correlations to analyze the relations between number of neurons
with CHMP2B-positive GVDs and phosphorylated tau accumu-
lation. Partial correlation analysis reduces the potential for
misleading interpretation of data and in the current study,
provided a more rigorous investigation of the relationships
between the variables. We interpreted coefficients ..5 as strong
correlations [61].
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